only with
Alembic Pharmaceuticals Ltd.
Alembic Pharma
Alembic Pharmaceuticals Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Small-cap - With a market cap of ₹144.86 Cr.
| EX-Date | Purpose |
|---|---|
| 04 05 2021 | Dividend & Audited Results |
| 26 07 2021 | Quarterly Results |
| 10 11 2021 | Quarterly Results |
| 10 02 2022 | Quarterly Results |
| 02 05 2022 | Audited Results & Dividend |
| 04 08 2022 | Quarterly Results & Interim Dividend |
| 11 11 2022 | Quarterly Results |
| 01 02 2023 | Quarterly Results |
| 05 05 2023 | Final Dividend & Audited Results |
| 04 08 2023 | Quarterly Results |
| 07 11 2023 | Quarterly Results |
| 05 02 2024 | Quarterly Results |
| 07 11 2024 | Quarterly Results |
| 03 02 2025 | Quarterly Results |
| 06 05 2025 | Audited Results & Final Dividend |
| 05 08 2025 | Quarterly Results |
| 04 11 2025 | Quarterly Results |
| 05 02 2026 | Quarterly Results |
| 15 05 2026 | Audited Results & Final Dividend |
News
Alembic Pharmaceuticals gets USFDA’s final approval for Haloperidol tablets
The company has a cumulative total of 240 ANDA approvals (221 final approvals and 19 tentative approvals) from USFDA
Alembic Pharmaceuticals gets USFDA’s final nod for Levothyroxine Sodium Tablets
Levothyroxine sodium tablets are indicated as a replacement therapy in primary, secondary, and tertiary congenital or acquired hypothyroidism
Alembic Pharmaceuticals gets EIR from USFDA for Injectable facility in Gujarat
The USFDA had conducted an unannounced cGMP inspection from February 9, 2026 to February 18, 2026
Alembic Pharmaceuticals gets USFDA’s tentative nod for Darolutamide Tablets
The approved ANDA is therapeutically equivalent to the reference listed drug product, Nubeqa Tablets, 300 mg, of Bayer
Alembic Pharmaceuticals gets USFDA’s final approval for Fingolimod Capsules
Alembic has a cumulative total of 237 ANDA approvals from USFDA
Alembic Pharmaceuticals incorporates wholly owned subsidiary in Germany
The objective of incorporation is to explore new business opportunities in this geography to promote, sale and distribute pharmaceuticals product(s) of the company
Alembic Pharmaceuticals incorporates subsidiary in Philippines
The company has incorporated a subsidiary to explore new business opportunities in this geography to promote, sale and distribute pharmaceuticals product(s) of the company
Alembic Pharmaceuticals gets USFDA’s final nod for Methotrexate Injection
Alembic has a cumulative total of 236 ANDA approvals from USFDA
Alembic Pharmaceuticals secures USFDA’s final approval for ‘Dapagliflozin Tablets’
The company is eligible for 180 days of shared generic drug exclusivity
Alembic Pharma gets USFDA’s final nod for Paroxetine Extended-Release Tablets
The approved sANDA is therapeutically equivalent to the reference listed drug product, Paxil CR Tablets, 12.5 mg, of Apotex Inc
Alembic Pharmaceuticals incorporates subsidiary in Thailand
The Company holds 99.99% stake in Alembic Pharmaceuticals (Thailand) Co
Alembic Pharma gets USFDA’s final approval for Lamotrigine Orally Disintegrating Tablets
Alembic has a cumulative total of 235 ANDA approvals from USFDA
Alembic Pharma gets USFDA’s final approval for Efinaconazole Topical Solution
Alembic was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification
Alembic Pharmaceuticals receives two observations for Karakhadi Injectable Facility
The USFDA has conducted an unannounced cGMP inspection at the said facility from February 9, 2026 to February 18, 2026
Alembic Pharma gets USFDA’s approval for Carbidopa, Levodopa and Entacapone Tablets
Alembic has a cumulative total of 234 ANDA approvals from USFDA
Alembic Pharmaceuticals reports marginal fall in Q3 consolidated net profit
Total consolidated income of the company increased by 11.13% at Rs 1891.81 crore for Q3FY26
Alembic Pharmaceuticals gets USFDA’s final approval for Difluprednate Ophthalmic Emulsion
Alembic has a cumulative total of 233 ANDA approvals from USFDA
Alembic Pharmaceuticals gets USFDA’s tentative approval for Bosutinib Tablets
The company has a cumulative total of 232 ANDA approvals (212 final approvals and 20 tentative approvals) from USFDA
Alembic Pharmaceuticals gets USFDA’s final nod for Travoprost Ophthalmic Solution USP
Travoprost Ophthalmic Solution USP, 0.004%, has an estimated market size of $61 million for twelve months ending September 2025
Alembic Pharma gets USFDA’s nod for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension
The company is eligible for 180 days of CGT exclusivity upon commercialization
Alembic Pharmaceuticals gets USFDA’s final nod for Diltiazem Hydrochloride Tablets
The company has a cumulative total of 230 ANDA approvals (210 final approvals and 20 tentative approvals) from USFDA
Alembic Pharmaceuticals gets USFDA’s final nod for Dexlansoprazole Delayed-Release Capsules
The company has a cumulative total of 229 ANDA approvals (209 final approvals and 20 tentative approvals) from USFDA
Alembic Pharmaceuticals gets USFDA’s final nod for Sumatriptan Injection USP
Alembic has a cumulative total of 228 ANDA approvals (207 final approvals and 21 tentative approvals) from USFDA
Alembic Pharma gets USFDA’s nod for Triamcinolone Acetonide Injectable Suspension
The company has a cumulative total of 227 ANDA approvals (206 final approvals and 21 tentative approvals) from USFDA
Alembic Pharmaceuticals gets USFDA’s final approval for Paroxetine Extended-Release Tablets
The approved ANDA is therapeutically equivalent to the reference listed drug product, Paxil CR Extended-Release Tablets, 25 mg and 37.5 mg, of Apotex Inc
Alembic Pharmaceuticals gets EIR from USFDA for API - I, API - II facility at Panelav
The inspection was conducted from May 26, 2025 to May 31, 2025
Alembic Pharmaceuticals gets USFDA’s final approval for Phytonadione Injectable Emulsion USP
Phytonadione Injectable Emulsion is indicated for the treatment of hypoprothrombinemia due to vitamin K deficiency or interference
Alembic Pharmaceuticals gets USFDA’s final approval for Macitentan Tablets
Macitentan Tablets, 10 mg, have an estimated market size of $1,180 million for twelve months ending June 2025 according to IQVIA
Alembic Pharmaceuticals gets USFDA’s final approval for Tretinoin Cream
The company has a cumulative total of 224 ANDA approvals (202 final approvals and 22 tentative approvals)
Alembic Pharmaceuticals reports 15% rise in Q1 consolidated net profit
The consolidated total income of the company increased by 9.81% at Rs 1717.22 crore for Q1FY26
Alembic Pharmaceuticals gets USFDA’s final approval for Carbamazepine Extended-Release Tablets
Alembic has a cumulative total of 225 ANDA approvals (202 final approvals and 23 tentative approvals) from USFDA
Alembic Pharmaceuticals’ arm to acquire Utility Therapeutics
The objective behind the acquisition is to market the USFDA approved product and underdevelopment product owned by the Utility in USA
Alembic Pharmaceuticals gets final nod for Doxorubicin Hydrochloride Liposome Injection
The company has a cumulative total of 224 ANDA approvals (201 final approvals and 23 tentative approvals) from USFDA
Alembic Pharmaceuticals gets EIR from USFDA for API-III facility at Karakhadi
Earlier, the company had successfully completed the USFDA inspection for its API-III Facility located at Karakhadi
USFDA concludes inspection at Alembic Pharmaceuticals’ Gujarat API-I & II facility
The USFDA issued a Form 483 with four observations
Alembic Pharmaceuticals receives USFDA’s final approval for Bosutinib Tablets
The company has a cumulative total of 223 ANDA approvals (200 final approvals and 23 tentative approvals) from USFDA
Alembic Pharmaceuticals gets USFDA’s nod for Amlodipine and Atorvastatin Tablets
The company has a cumulative total of 223 ANDA approvals (199 final approvals and 24 tentative approvals) from USFDA
Alembic Pharmaceuticals gets USFDA’s final nod for Rivaroxaban Tablets USP
Rivaroxaban Tablets USP, 2.5 mg, has an estimated market size of $445 million for twelve months ending March 2025
Alembic Pharmaceuticals receives USFDA’s final approval for Ticagrelor Tablets
The company has a cumulative total of 222 ANDA approvals from USFDA
Alembic Pharmaceuticals commissions new manufacturing facility in Madhya Pradesh
The investment made for said manufacturing facility is approximately Rs 205 crore
Alembic Pharmaceuticals gets USFDA’s nod for Carbamazepine Tablets
Alembic has a cumulative total of 222 ANDA approvals (196 final approvals and 26 tentative approvals) from USFDA
Alembic Pharmaceuticals receives USFDA’s final approval for Pantoprazole Sodium Injection
Alembic has a cumulative total of 221 ANDA approvals from USFDA
Alembic Pharmaceuticals completes USFDA inspection for API-III Facility at Karakhadi
The inspection was conducted from March 17, 2025 to March 21, 2025
Alembic Pharmaceuticals’ arm incorporates wholly-owned subsidiary in USA
Alembic Global Holding SA will be making a remittance to Alembic LifeSciences Inc. towards subscription of 100% shareholding
USFDA concludes inspection at Alembic Pharmaceuticals’ Vadodara facility
The USFDA issued a form 483 with one procedural observation
Alembic Pharma gets USFDA’s approval for Brexpiprazole Tablets
Alembic has a cumulative total of 220 ANDA approvals from USFDA
Alembic Pharmaceuticals gets USFDA’s final approval for Divalproex Sodium Delayed-Release Capsules
The company has a cumulative total of 220 ANDA approvals from USFDA
Alembic Pharmaceuticals completes ANVISA GMP audit for API-II Facility in Panelav
The inspection was conducted from September 16, 2024 to September 20, 2024
Alembic Pharma gets USFDA’s tentative nod for Olopatadine Hydrochloride Ophthalmic Solution
The company has a cumulative total of 219 ANDA approvals (192 final approvals and 27 tentative approvals) from USFDA
USFDA completes inspection at Alembic Pharmaceuticals’ Solid Oral Formulation Facility
The USFDA issued a Form 483 with five procedural observations
Alembic Pharma gets USFDA’s final approval for Ivabradine Tablets
The company has a cumulative total of 218 ANDA approvals from USFDA
Alembic Pharma gets final nod for Diltiazem Hydrochloride Extended-Release Capsules
Diltiazem Hydrochloride Extended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg have an estimated market size of $105.3 million for twelve months ending June 2024 according to IQVIA
Alembic Pharma gets USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
USFDA completes inspection at Alembic Pharmaceuticals’ Oncology formulation facility
The inspection was successfully completed without any Form 483 observation
Alembic Pharmaceuticals gets final nod for Alcaftadine Ophthalmic Solution
Alembic has a cumulative total of 216 ANDA approvals (189 final approvals and 27 tentative approvals) from USFDA
Alembic Pharmaceuticals gets USFDA’s final approval for Lamotrigine Extended-Release Tablets
Alembic has a cumulative total of 216 ANDA approvals from USFDA
Alembic Pharmaceuticals gets EIR from USFDA for Oral Solid Formulation Facility
With this, for all the company’s USFDA facilities, EIRs are in place
Alembic Pharmaceuticals gets USFDA’s final approval for Paliperidone Extended-Release tablets
The company has a cumulative total of 215 ANDA approvals (187 final approvals and 28 tentative approvals) from USFDA
Alembic Pharma gets tentative USFDA’s nod for breast cancer drug
It is the generic equivalent of Novartis’ Kisqali tablets
USFDA conducts inspection at Alembic Pharmaceuticals’ Oncology Formulation Facility
The USFDA issued a Form 483 with four procedural observations
Alembic Pharmaceuticals to invest $1.0 million in RIGImmune
This investment will help the company to get into niche segment of new chemical entities
Alembic Pharmaceuticals reports marginal rise in Q2 consolidated net profit
Total consolidated income of the company increased by 8.79% at Rs 1,605.08 crore for Q2FY24
Alembic Pharmaceuticals’ arm recalls 82,400 bottles of Tobramycin Ophthalmic Solution in US
New Jersey-based Alembic Pharmaceuticals Inc is recalling the affected lot (0.3 per cent, 5ml bottle) due to ‘Failed Impurities/Degradation Specifications’
Alembic Pharmaceuticals reports consolidated net profit of Rs 121 crore in Q1FY24
Total consolidated income of the company increased by 18.57% at Rs 1,497.81 crore for Q1FY24
Alembic Pharmaceuticals gets EIR for Solid Oral Formulation Facility (F-4) at Vadodara
The Company had also started receiving approvals manufactured at this facility
Alembic Pharma gets USFDA’s final approval for Brimonidine Tartrate Ophthalmic Solution
Brimonidine Tartrate Ophthalmic Solution, 0.15% has an estimated market size of $97 million for twelve months ending Dec 2022
Alembic Pharmaceuticals completes USFDA’s inspection at Derma Facility
The inspection was conducted from March 6, 2023 to March 10, 2023
Alembic Pharmaceuticals gets USFDA’s tentative approval for Brexpiprazole Tablets
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg have an estimated market size of $1.6 billion for twelve months ending December 2022
Alembic Pharma gets USFDA’s final approval for Prazosin Hydrochloride Capsules
Prazosin Hydrochloride Capsule is indicated for the treatment of hypertension, to lower blood pressure
Alembic Pharmaceuticals gets USFDA’s final approval for Fluorouracil Injection
Alembic has a cumulative total of 182 ANDA approvals (159 final approvals and 23 tentative approvals) from USFDA
Alembic Pharmaceuticals gets USFDA’s final approval for Docetaxel Injection
Alembic has a cumulative total of 181 ANDA approvals (158 final approvals and 23 tentative approvals) from USFDA
Alembic Pharmaceuticals receives EIR for Injectable Facility at Karkhadi
The company has already started receiving ANDA approvals manufactured at this facility
Alembic Pharmaceuticals reports 29% fall in Q3 consolidated net profit
Total consolidated income of the company increased by 17.29% to Rs 1,509.46 crore for Q3FY23
Alembic Pharmaceuticals receives USFDA’s tentative approval for Acalabrutinib Capsules
Acalabrutinib Capsules, 100 mg, have an estimated market size of $1.5billion for twelve months ending Sep 2022 according to IQVIA
Alembic Pharmaceuticals gets USFDA’s final nod for Fesoterodine Fumarate Extended-Release Tablets
Alembic has a cumulative total of 179 ANDA approvals (157 final approvals and 22 tentative approvals) from USFDA
Alembic Pharmaceuticals gets final nod for Fulvestrant Injection from USFDA
The company has received a cumulative total of 179 ANDA approvals (156 final approvals and 23 tentative approvals) from USFDA
Alembic Pharmaceuticals receives PAS approval from USFDA for Pregabalin Capsules
Alembic has a cumulative total of 178 ANDA approvals from USFDA
USFDA conducts pre-approval inspection at Alembic Pharmaceuticals’ Jarod facility
The USFDA issued a Form 483 with 5 procedural observations
USFDA issues EIR to Alembic Pharmaceuticals’ Oncology Injectable Formulation facility at Panelav
The Company had also started receiving ANDA approval manufactured at this facility
Alembic Pharmaceuticals gets USFDA’s final approval for Desonide Cream
The ANDA was filed by Aleor Dermaceuticals which was amalgamated with Alembic
Alembic Pharmaceuticals gets USFDA’s final approval for Diclofenac Sodium Topical Solution
Diclofenac Sodium Topical Solution is indicated for the treatment of the pain of osteoarthritis of the knee(s)
Alembic Pharmaceuticals gets USFDA’s approval for Nifedipine Extended-Release Tablets
Alembic has a cumulative total of 177 ANDA approvals from USFDA
Alembic Pharmaceuticals reports 19% fall in Q2 consolidated net profit
Total consolidated income of the company increased by 12.35% at Rs 1475.34 crore for Q2FY23
Alembic Pharmaceuticals gets USFDA’s final approval for Cyclophosphamide Capsules
Cyclophosphamide Capsules have an estimated market size of $ 8 million for twelve months ending Sep 2022 according to IQVIA
Alembic Pharmaceuticals gets final nod for Ketorolac Tromethamine Injection
Ketorolac Tromethamine Injection USP has an estimated market size of $59 million for twelve months ending June 2022
Alembic Pharmaceuticals gets final approval for Mesalamine Extended-Release Capsules from USFDA
Mesalamine Extended-Release Capsules USP, 0.375 g, have an estimated market size of $133 million for twelve months ending June 2022
Alembic Pharmaceuticals gets USFDA’s approval for Glycopyrrolate Injection USP
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022
Alembic Pharmaceuticals gets final nod for Paclitaxel Injection from USFDA
The company has a cumulative total of 172 ANDA approvals (148 final approvals and 24 tentative approvals) from USFDA
USFDA concludes inspection at Alembic Pharmaceuticals’ Bioequivalence facility
The inspection was conducted from October 17, 2022 to October 21, 2022
Alembic Pharmaceuticals gets 4 observations from USFDA for Panelav facility
The Company is committed to maintain the highest quality standards and compliance at all times
USFDA concludes inspection at Alembic Pharma’s injectable facility at Gujarat
The company is committed to maintain the highest quality standards and compliance at all times
Alembic Pharmaceuticals gets USFDA’s final approval for Chlorthalidone Tablets
The company has a cumulative total of 171 ANDA approvals from USFDA
Alembic Pharma’s arm gets USFDA’s final approval for Adapalene and Benzoyl Peroxide Topical Gel
Alembic has received a cumulative total of 170 ANDA approvals from USFDA
Alembic Pharmaceuticals reports consolidated net loss of Rs 66 crore in Q1
Total consolidated income of the company decreased by 5.03% at Rs 1,263.22 crore for Q1FY23
Alembic Pharmaceuticals gets USFDA tentative nod for Dasatinib tablets
Dasatinib Tablets have an estimated market size of $1465 million for twelve months ending Dec 2021 according to IQVIA
Alembic Pharmaceuticals gets final nod from USFDA for Pirfenidone Tablets
Pirfenidone Tablets, 267 mg and 801 mg have an estimated market size of $ 548 million for twelve months ending December 2021